ARK Genomic Revolution UCITS ETF Class A USD Acc
| Issuer: ARK Investment Management |
| Asset Class: Equity |
| TER: 75bps |
| Trading Currency: USD |
| Pays Income: False |
| Listing Date: 19 Apr 2024 |
| Ticker: ARKG |
| ISIN: IE000O5M6XO1 |
This fund offers concentrated exposure to the genomics revolution, a field at the intersection of healthcare and technology that is poised for significant long-term growth. The investment strategy focuses on companies engaged in disruptive innovation across several key areas: CRISPR and gene-editing technologies, which hold the potential to cure genetic diseases; targeted therapeutics that promise more effective treatments for conditions like cancer; advanced molecular diagnostics for earlier and more accurate disease detection; bioinformatics, which uses big data to analyze biological information; and developments in stem cells and agricultural biology. The portfolio is actively managed, aiming to identify and invest in the leading businesses that are driving these scientific advancements forward and are expected to benefit from their widespread adoption.
The core investment thesis is built on the belief that the convergence of next-generation DNA sequencing, artificial intelligence, and novel gene therapies is creating a paradigm shift in healthcare and beyond. By investing in this theme, individuals can gain access to companies at the forefront of developing personalized medicine, reducing healthcare costs through preventative care, and improving quality of life on a global scale. This fund provides a way to participate in the growth trajectory of one of the most transformative technological trends of our time.
As a thematic and high-conviction portfolio, the fund is suitable for investors with a long-term horizon and a higher tolerance for risk. The companies within the portfolio are often in the early stages of development and commercialization, making their stock prices potentially more volatile than the broader market. The strategy is designed to capture the upside from scientific breakthroughs and the subsequent commercial success of these pioneering firms, offering a pure-play investment in the future of medicine and biology.
